Recent developments of interest in cardiovascular medicine
— Recent developments of interest in cardiovascular medicine
by Nicole Lou, Senior Staff Writer, MedPage Today
July 28, 2026
• 2 min read
The FDA approved autoinjectable furosemide (Furoscix ReadyFlow) for the treatment of edema in adults with heart failure or chronic kidney disease, MannKind announced.
FDA approves self-administered furosemide injector to treat edema in heart failure, CKD
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - MannKind (NASDAQ:M
FDA Clears CorVista® System PCWP Add-On as a Noninvasive Test For Elevated Pulmonary Capillary Wedge Pressure
New International Consensus Redefines Heart Failure Diagnosis, Putting Filling Pressure and Primary Care at the Center
Scoring tools help with GDMT optimization for heart failure
MannKind announced the FDA approved an at-home furosemide self-injection for treatment of edema in adults with HF or chronic…
MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement…
Recent developments of interest in cardiovascular medicine
Recent developments of interest in cardiovascular medicine
Digitalis glycosides may be a safe and tolerable addition to optimal guideline medical therapy to reduce worsening heart failure…
Finerenone was associated with early and sustained reductions in systolic blood pressure among patients with heart failure with…
